Grace Therapeutics, Inc. (GRCE)

Compare

2.2850

-0.0250

(-1.08%)

As of 12:48:12 PM EDT. Market Open.

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. “We are thrilled to announce the addition of Keith and Edward to our Board,” stated Jerome

GlobeNewswire 23 days ago

GRCE
-1.08%
MTNB

ONVO
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming TD Cowen

GlobeNewswire last month

GRCE
-1.08%
GRCE: STRIVE-ON Results Reported

By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported fiscal year (FY) third quarter results following a series of announcements regarding conference participation, the raise of additional capital and results from the Phase III STRIVE-ON trial for GTx-104. The most important information was the data from the Phase III safety trial.

Zacks Small Cap Research last month

GRCE
-1.08%
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025 Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J., Feb.

GlobeNewswire last month

GRCE
-1.08%
Grace Therapeutics secures $15m for GTx-104 pre-commercial development

The upfront net proceeds from this private placement will be allocated for general corporate purposes.

Pharmaceutical Technology last month

GRCE
-1.08%
Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million

Grace Therapeutics (GRCE) rose nearly 8% in recent Monday trading after it said it entered into secu

PREMIUM
MT Newswires last month

GRCE
-1.08%
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

On Monday, Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipine in patients hospitalized with aneurysmal Subarachnoid Hemorrhage (aSAH). aSAH is bleeding over the brain’s surface in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. The study met its primary endpoint and provides evidence of clinical benefit compared to orally administere

Benzinga last month

GRCE
-1.08%
Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an additional $15 million in potential warrant exercise proceeds for an aggregate of up to approximately $30 million in potential total gross proceeds PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therap

GlobeNewswire last month

GRCE
-1.08%
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion t

GlobeNewswire last month

GRCE
-1.08%
3 US Penny Stocks With Market Cap Under $70M

As the S&P 500 edges toward new highs amidst mixed trading sessions, investors are paying close attention to smaller market segments for potential opportunities. Penny stocks, though an older term, continue to represent a compelling area of interest due to their association with smaller or emerging companies that might offer significant growth potential. By focusing on those with strong financials and solid fundamentals, investors can find unique opportunities in this often-overlooked segment...

Simply Wall St. 2 months ago

GBIO

GRCE
-1.08%
Grace Therapeutics to Participate in Upcoming Investor Events January 2025

PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that Chief Executive Officer Prashant Kohli will partici

GlobeNewswire 2 months ago

GRCE
-1.08%
Grace Therapeutics And 2 Other US Penny Stocks Worth Watching

As the U.S. stock market reacts positively to benign inflation data, investors are exploring various opportunities across different sectors. Penny stocks, often representing smaller or newer companies, continue to attract attention due to their potential for significant returns despite the term's outdated connotations. By focusing on those with robust financials and a clear growth trajectory, investors can uncover valuable opportunities in these lesser-known stocks.

Simply Wall St. 3 months ago

XFOR

GRCE
-1.08%
GRCE: aSAH KOL Summary

By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) held a key opinion leader (KOL) event on November 20 th , 2024 featuring Abhishek Ray, MD of University Hospitals and Andrew Webb, PharmD, BCCCP of Massachusetts General Hospital. The event was hosted by Grace’s CEO Prashant Kohli. As Grace enters the final stretch of its STRIVE-ON trial

Zacks Small Cap Research 3 months ago

GRCE
-1.08%
Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

PRINCETON, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that the Company will be participating in the mid-year c

GlobeNewswire 3 months ago

GRCE
-1.08%
GRCE: FY:25 Second Quarter Results

By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported financial results and achievements for its fiscal second quarter ending September 30 th , 2024 on November 13 th . Activity since the beginning of its fiscal year in March includes completion of enrollment in the STRIVE-ON trial, a corporate name change to Grace Therapeutics and

Zacks Small Cap Research 4 months ago

GRCE
-1.08%
Grace Therapeutics And 2 Other US Penny Stocks To Watch

As the U.S. stock market grapples with lower performance amid a downturn in major indices and tech stocks, investors are increasingly looking for alternative opportunities. Penny stocks, often associated with smaller or emerging companies, can still offer potential value and growth when backed by solid financials. In this article, we will examine Grace Therapeutics alongside two other penny stocks that may stand out for their financial strength in today's challenging market landscape.

Simply Wall St. 4 months ago

GRCE
-1.08%
ASRV
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update

STRIVE-ON Data Readout Expected First Calendar Quarter 2025; NDA Submission on Track for 1H Calendar 2025 Completed Corporate Re-Branding, Connecting Company to Rich Scientific Legacy of Grace Therapeutics Announced Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 Hosting Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage November 20, 2024 Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -

GlobeNewswire 4 months ago

GRCE
-1.08%
GRCE: Initiating Coverage – From Confusion to Infusion

By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT We are initiating coverage of Grace Therapeutics, Inc. (NASDAQ:GRCE) with a valuation of $12.50 per share. This value is based on our estimates for the successful development and commercialization of GTX-104 in patients being treated for aneurysmal subarachnoid hemorrhage (aSAH) in the United States and in developed regions

Zacks Small Cap Research 4 months ago

GRCE
-1.08%
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced it will host a virtual key opinion leader (KOL) event on Wednesday, November 20, 2024 at 2:00 PM ET. To register, click here. The event will feature Abhish

GlobeNewswire 5 months ago

GRCE
-1.08%
OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR

NASDAQ:GRCE | NASDAQ:ACST Since the recording of this interview, the company has changed its name to Grace Therapeutics and is now trading under NASDAQ:GRCE. John Viglotti: Hello, and welcome to Virtual Investor Conferences. My name's John Viglotti, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you joined us for our next presentation from Acasti

Zacks Small Cap Research 5 months ago

GRCE
-1.08%

Performance Overview

Return	GRCE	S&P 500 (^GSPC)
YTD	-38.90%	-7.10%
1-Year	-32.40%	+4.85%
3-Year	-69.04%	+20.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Grace Therapeutics, Inc. (GRCE)

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

GRCE: STRIVE-ON Results Reported

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Grace Therapeutics secures $15m for GTx-104 pre-commercial development

Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

3 US Penny Stocks With Market Cap Under $70M

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Grace Therapeutics And 2 Other US Penny Stocks Worth Watching

GRCE: aSAH KOL Summary

Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

GRCE: FY:25 Second Quarter Results

Grace Therapeutics And 2 Other US Penny Stocks To Watch

Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update

GRCE: Initiating Coverage – From Confusion to Infusion

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR

Performance Overview